PCV20 is a pneumococcal conjugate vaccine that protects against 20 strains of the bacterium that causes pneumonia, meningitis, and bloodstream infections. Sold under the brand name Prevnar 20 and made by Pfizer, it’s approved for anyone from 6 weeks of age through adulthood. It replaced an older vaccine (PCV13) that covered only 13 strains, offering significantly broader protection in a single shot.
What PCV20 Protects Against
Streptococcus pneumoniae, often just called pneumococcus, is a group of bacteria with dozens of distinct strains (called serotypes). Not all of them cause serious illness at the same rate. PCV20 targets the 20 serotypes responsible for a large share of severe pneumococcal disease: types 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.
The seven additional serotypes beyond what PCV13 covered (8, 10A, 11A, 12F, 15B, 22F, and 33F) were chosen because they account for a meaningful portion of pneumococcal infections in adults, particularly those over 65. Before PCV20 existed, the only way to get protection against those extra strains was a separate, older-style vaccine called PPSV23, which worked differently and often required a two-shot sequence alongside PCV13. PCV20 collapses that complexity into one vaccine.
How It Differs From Older Pneumococcal Vaccines
For years, the standard adult approach was to receive PCV13 first, then follow up with PPSV23 at least a year later. PCV13 produced strong, long-lasting immune memory but covered fewer strains. PPSV23 covered more strains but triggered a weaker type of immune response that faded faster. PCV20 combines the broader coverage with the stronger conjugate technology, eliminating the need for two separate vaccines in most cases.
PCV15 (Vaxneuvance, by Merck) is another option that covers 15 serotypes. When PCV15 is used instead of PCV20 for adults, a follow-up dose of PPSV23 is still recommended to fill the coverage gap. Choosing PCV20 avoids that extra step. For children, either PCV15 or PCV20 can be used for the routine series, and no additional vaccine is needed afterward with either option.
Who Should Get It
The CDC recommends PCV20 (or PCV15 or the newer PCV21) for two main groups of adults who have never received a pneumococcal conjugate vaccine:
- Adults 50 and older
- Adults 19 through 49 with certain risk conditions, including chronic heart, lung, or liver disease, diabetes, alcoholism, cochlear implants, cerebrospinal fluid leaks, weakened immune systems, HIV, sickle cell disease, or a missing or nonfunctioning spleen
If you’re 65 or older and previously received both PCV13 (at any age) and PPSV23 (at or after 65), you have the option to get PCV20 for the additional serotype coverage, but it’s not strictly required. You can discuss with your provider whether the extra protection is worth it based on your health status.
The Childhood Vaccine Schedule
For infants, PCV20 is given as a routine four-dose series: one dose each at 2 months, 4 months, 6 months, and 12 through 15 months. This is the same schedule that was used for PCV13, so the switch doesn’t change anything about the timing of well-child visits. Parents choosing between PCV15 and PCV20 for their child can use either. Both follow the same four-dose timeline, and neither requires an additional pneumococcal vaccine afterward.
Children who started their series with PCV13 or PCV15 can finish with PCV20. The vaccines are considered interchangeable within the series.
How It’s Given
PCV20 is an intramuscular injection, meaning it goes into the muscle rather than under the skin. For infants and toddlers, the shot is given in the thigh. For older children and adults, it goes in the upper arm (deltoid muscle). It can typically be given at the same visit as other vaccines, like the flu shot, in a different arm or injection site.
Common Side Effects
PCV20 causes the same kinds of short-lived reactions you’d expect from most vaccines. In clinical trials, the most frequently reported side effects in adults were:
- Injection site pain: 67 to 76% of recipients
- Fatigue: 21 to 34%
- Muscle aches: 27 to 29%
- Headache: 19 to 27%
- Injection site swelling: 15 to 22%
These reactions typically peak within the first day or two and resolve on their own. Serious adverse events are rare. The side effect profile is comparable to what was seen with PCV13, which had been in widespread use since 2010.
Why Pneumococcal Vaccination Matters
Pneumococcal bacteria are a leading cause of vaccine-preventable death in adults over 65 and in young children. The infections they cause range from ear infections and sinus infections (less serious) to pneumonia, meningitis, and bacteremia (potentially fatal). Adults with weakened immune systems or chronic diseases face especially high risk, as do children under 2 whose immune systems are still developing.
Before pneumococcal conjugate vaccines were introduced for children in 2000, invasive pneumococcal disease was far more common. Vaccination has dramatically reduced those numbers, but the bacteria still circulate widely, and the strains not covered by older vaccines have gradually filled the gap. PCV20’s expanded coverage is designed to address that shift.